Want to keep learning?

This content is taken from the UEA (University of East Anglia)'s online course, Using Personalized Medicine and Pharmacogenetics. Join the course to learn more.

Skip to 0 minutes and 3 secondsHello. we're now in the final part of our course and we will focus on cancer pharmacogenetics this week. Personalised medicine is particularly advanced with oncology clinics. Both constitutional genetics and somatic genetics need to be considered this week. The final steps of this course will involve a critical appraisal of some genetic tests that are predictive of the severe toxicity associated with one particular class of chemotherapy. We will consider the balance that has to be struck between gaining benefit from treatment and the risk of adverse side effects.

Welcome to Week 3

Cancer is considered to be a genetic disease and pharmacogenetics is already being applied to its management.

Treatment stratification involves the use of companion diagnostic tests and personalised medicine may depend on genome sequencing in the near future.

Most published work about the clinical translation of pharmacogenetics and pharmacogenomics relates to the management of cancer.

In this session we will consider the application of genetic biomarkers with proven clinical utility for treatment stratification.

We will also consider how whole genome sequencing may affect classification paradigms and lead to individualised treatment protocols.

Share this video:

This video is from the free online course:

Using Personalized Medicine and Pharmacogenetics

UEA (University of East Anglia)